Navigation Links
Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
Date:3/30/2011

STEWARTVILLE, Minn., March 30, 2011 /PRNewswire/ -- Rochester Medical Corporation (Nasdaq: ROCM) announced that the shareholders of Fornix BioSciences N.V. today approved the previously announced sale of Laprolan B.V. its Medical Supplies Division and wholly owned subsidiary to Rochester Medical Corporation.

Rochester Medical expects the transaction to close in the near term, and under the terms of the Share Purchase Agreement between Rochester Medical and Fornix, be deemed retroactive to January 1, 2011.  For more information regarding this transaction please refer to the Company's January 12, 2011 press release.

This press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, but are not limited to, statements about the expected completion of the acquisition of Laprolan.  Such statements are based on currently available information, operating plans and management's expectations about future events and trends.  Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2010.  Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made.  The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Rochester Medical Corporation develops, manufactures, and markets latex-free disposable medical catheters and devices for urological and continence care applications.  The Company markets under its own Rochester Medical® brand and under existing private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600.  More information about Rochester Medical is available on its website at http://www.rocm.com.


'/>"/>
SOURCE Rochester Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
2. Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders
3. Caraco Announces Merger Agreement with Sun Pharma; Caraco Public Shareholders to Receive $5.25 Cash per Share
4. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
5. Amarin Provides 2010 Year-End Review to Shareholders
6. BD Announces Webcast of Annual Meeting of Shareholders
7. Penwest Pharmaceuticals Shareholders Approve Merger With Subsidiary of Endo Pharmaceuticals
8. Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010
9. China Sky One Medical, Inc. Reports Outcome of Annual Meeting of Shareholders
10. Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
11. United American Healthcare Corporation Announces Results of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... -- This report provides all the information you require ... activities since 2010. Download the full report: ... and Alliance since 2010 report provides an in-depth insight ... leading life sciences companies. On demand company ... the most up to date deal and company data. ...
(Date:2/28/2017)... Feb. 27, 2017 This report provides all ... its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:2/28/2017)... , Feb 28, 2017 Research ... Enzyme Supplements Market Forecasts 2014-2025" report to their offering. ... ... USD 1.6 billion by 2025. Growing consumer awareness regarding the ... health is expected to stimulate industry growth over the forecast ...
Breaking Medicine Technology:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Much attention has ... for women who become dependent on opioid painkillers has fallen short. From 1999 until ... to a 237% increase in fatal overdoses in male populations.(1) , The proportion of ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... Periodontitis is a chronic inflammatory gum condition that occurs when the bacteria in plaque ... cleaning, also referred to as a scaling and root planing or SRP, and can ...
(Date:2/27/2017)... ... , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and ... for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss ... compiled into a single volume a compelling argument that the disease does exist in ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley ... to announce a new informational post on robotic hair transplantation. San Francisco residents ... hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can ...
Breaking Medicine News(10 mins):